Challenges enrolling patients with acute ischemic stroke into cell therapy trials

Area of Science:

• Neurology
• Regenerative Medicine
• Clinical Trials

Background:

• Acute ischemic stroke remains a leading cause of long-term disability.
• Autologous bone marrow-derived mononuclear cells (MNCs) show preclinical potential for neurological recovery.
• Cell-based therapies offer a novel therapeutic avenue for stroke patients.

Purpose of the Study:

• To evaluate the safety and feasibility of infusing autologous bone marrow-derived mononuclear cells (MNCs) in patients with acute ischemic stroke.
• To identify practical challenges and barriers in conducting a phase I clinical trial for this novel cell therapy.
• To provide lessons learned for optimizing future clinical trial designs in stroke cell therapy.

Main Methods:

• Phase I clinical trial design.
• Recruitment and treatment of patients with acute ischemic stroke.
• Monitoring of safety and feasibility parameters post-infusion.

Main Results:

• The phase I trial successfully assessed the safety and feasibility of autologous MNC infusion.
• Practical challenges were identified during trial execution.
• Key lessons were learned for future clinical trial planning.

Conclusions:

• Autologous bone marrow-derived MNC infusion is a feasible and potentially safe investigational therapy for acute ischemic stroke.
• Understanding and addressing practical barriers is crucial for advancing cell therapies in clinical practice.
• This study provides a foundation for designing larger, more robust clinical trials for stroke cell therapy.